Neuropharmacology
June 1, 2026
Evan C Smith, Christos Iliopoulos-Tsoutsouvas, Markos-Orestis Georgiadis et al.
Despite being the most prevalently abused illicit drug class, the neurochemical effects of cannabinoids (CBs) in key reward-related brain regions are not fully understood. Here, we used in vivo microdialysis combined with liquid chromatograph mass spectrometry to delineate how single, intraperitoneal injections of delta-9-tetrahydrocannabinol (Δ9-THC), and synthetic partial (AM11101) and full...
Nature Communications
January 8, 2025
T. Thorsen, Yashraj Kulkarni, David A. Sykes et al.
Tetrahydrocannabinol (THC) is the principal psychoactive compound derived from the cannabis plant Cannabis sativa and approved for emetic conditions, appetite stimulation and sleep apnea relief. THC’s psychoactive actions are mediated primarily by the cannabinoid receptor CB1. Here, we determine the cryo-EM structure of HU210, a THC analog and widely used tool compound, bound to CB1 and its...
Molecular Pharmacology
December 2022
Taryn Bosquez-Berger, Sierra Wilson, Christos Iliopoulos-Tsoutsouvas et al.
The two main constituents of cannabis are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). While Δ9-THC pharmacology has been studied extensively, CBD-long considered inactive-is now the subject of vigorous research related to epilepsy, pain, and inflammation and is popularly embraced as a virtual cure-all. However, our understanding of CBD pharmacology remains limited, although CBD...
Journal of Pharmacology and Experimental Therapeutics
January 29, 2016
Brian D Kangas, Michael Z. Leonard, Vidyanand G Shukla et al.
The primary psychoactive ingredient of marijuana, Δ(9)-tetrahydrocannabinol (Δ(9)-THC), has medicinal value but also produces unwanted deleterious effects on cognitive function, promoting the search for improved cannabinergic therapeutics. The present studies used a battery of touchscreen procedures in squirrel monkeys to compare the effects of different types of cannabinergic drugs on several...
Psychopharmacology
March 2012
Torbjörn U C Järbe, Sherrica Tai, Brian J LeMay et al.
The endocannabinoid signaling system (ECS) has been targeted for developing novel therapeutics since ECS dysfunction has been implicated in various pathologies. Current focus is on chemical modifications of the hexahydrocannabinol (HHC) nabilone (Cesamet(®)). To characterize the novel, high-affinity cannabinoid receptor 1 (CB(1)R) HHC-ligand AM2389...